Skip to main content
Erschienen in: Inflammation Research 10-11/2022

25.07.2022 | Review

Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction

verfasst von: Weixin He, Peixian Chen, Qingquan Chen, Zongtong Cai, Peidong Zhang

Erschienen in: Inflammation Research | Ausgabe 10-11/2022

Einloggen, um Zugang zu erhalten

Abstract

At least 17 million people die from acute myocardial infarction (AMI) every year, ranking it first among causes of death of human beings, and its incidence is gradually increasing. Typical characteristics of AMI include acute onset and poor prognosis. At present, there is no satisfactory treatment, but development of coronary collateral circulation (CCC) can be key to improving prognosis. Recent research indicates that the levels of cytokines, including those related to promoting inflammatory responses and angiogenesis, increase after the onset of AMI. In the early phase of AMI, cytokines play a vital role in inducing development of collateral circulation. However, when myocardial infarction is decompensated, cytokine secretion increases greatly, which may induce a cytokine storm and worsen prognosis. Cytokines can regulate the activation of a variety of signal pathways and form a complex network, which may promote or inhibit the establishment of collateral circulation. We searched for published articles in PubMed and Google Scholar, employing the keyword “acute myocardial infarction”, “coronary collateral circulation” and “cytokine storm”, to clarify the relationship between AMI and a cytokine storm, and how a cytokine storm affects the growth of collateral circulation after AMI, so as to explore treatment methods based on cytokine agents or inhibitors used to improve prognosis of AMI.
Literatur
2.
Zurück zum Zitat Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, Kazakiewicz D, de Benito Rubio V, Ignatiuk B, Raisi-Estabragh Z, Pawlak A, Karagiannidis E, Treskes R, Gaita D, Beltrame JF, McConnachie A, Bardinet I, Graham I, Flather M, Elliott P, Mossialos EA, Weidinger F, Achenbach S, Atlas Writing Group ESoC. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022;43:716–799. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, Kazakiewicz D, de Benito Rubio V, Ignatiuk B, Raisi-Estabragh Z, Pawlak A, Karagiannidis E, Treskes R, Gaita D, Beltrame JF, McConnachie A, Bardinet I, Graham I, Flather M, Elliott P, Mossialos EA, Weidinger F, Achenbach S, Atlas Writing Group ESoC. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022;43:716–799.
3.
Zurück zum Zitat Zeymer U, Ludman P, Danchin N, Kala P, Laroche C, Sadeghi M, Caporale R, Shaheen SM, Legutko J, Iakobsishvili Z, Alhabib KF, Motovska Z, Studencan M, Mimoso J, Becker D, Alexopoulos D, Kereseselidze Z, Stojkovic S, Zelveian P, Goda A, Mirrakhimov E, Bajraktari G, Al-Farhan H, Šerpytis P, Raungaard B, Marandi T, Moore AM, Quinn M, Karjalainen PP, Tatu-Chitolu G, Gale CP, Maggioni AP, Weidinger F. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. Eur Heart J. 2021;42:4536–49. PubMedCrossRef Zeymer U, Ludman P, Danchin N, Kala P, Laroche C, Sadeghi M, Caporale R, Shaheen SM, Legutko J, Iakobsishvili Z, Alhabib KF, Motovska Z, Studencan M, Mimoso J, Becker D, Alexopoulos D, Kereseselidze Z, Stojkovic S, Zelveian P, Goda A, Mirrakhimov E, Bajraktari G, Al-Farhan H, Šerpytis P, Raungaard B, Marandi T, Moore AM, Quinn M, Karjalainen PP, Tatu-Chitolu G, Gale CP, Maggioni AP, Weidinger F. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. Eur Heart J. 2021;42:4536–49. PubMedCrossRef
4.
Zurück zum Zitat Shao C, Wang J, Tian J, Tang YD. Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol. 2020;1177:1–36. PubMedCrossRef Shao C, Wang J, Tian J, Tang YD. Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol. 2020;1177:1–36. PubMedCrossRef
6.
Zurück zum Zitat Song J, Murugiah K, Hu S, Gao Y, Li X, Krumholz HM, Zheng X. Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction in China. Heart. 2020;107:313–8. CrossRef Song J, Murugiah K, Hu S, Gao Y, Li X, Krumholz HM, Zheng X. Incidence, predictors, and prognostic impact of recurrent acute myocardial infarction in China. Heart. 2020;107:313–8. CrossRef
7.
Zurück zum Zitat Guan W, Venkatesh AK, Bai X, Xuan S, Li J, Li X, Zhang H, Zheng X, Masoudi FA, Spertus JA, Krumholz HM, Jiang L. Time to hospital arrival among patients with acute myocardial infarction in China: a report from China PEACE prospective study. Eur Heart J Qual Care Clin Outcomes. 2018;5:63–71. PubMedCentralCrossRef Guan W, Venkatesh AK, Bai X, Xuan S, Li J, Li X, Zhang H, Zheng X, Masoudi FA, Spertus JA, Krumholz HM, Jiang L. Time to hospital arrival among patients with acute myocardial infarction in China: a report from China PEACE prospective study. Eur Heart J Qual Care Clin Outcomes. 2018;5:63–71. PubMedCentralCrossRef
8.
Zurück zum Zitat Mahmud E, Dauerman HL, Welt FGP, Messenger JC, Rao SV, Grines C, Mattu A, Kirtane AJ, Jauhar R, Meraj P, Rokos IC, Rumsfeld JS, Henry TD. Management of acute myocardial infarction during the COVID-19 pandemic: A consensus statement from the society for cardiovascular angiography and interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Catheter Cardiovasc Interv. 2020;96:336–45. PubMedCrossRef Mahmud E, Dauerman HL, Welt FGP, Messenger JC, Rao SV, Grines C, Mattu A, Kirtane AJ, Jauhar R, Meraj P, Rokos IC, Rumsfeld JS, Henry TD. Management of acute myocardial infarction during the COVID-19 pandemic: A consensus statement from the society for cardiovascular angiography and interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Catheter Cardiovasc Interv. 2020;96:336–45. PubMedCrossRef
9.
Zurück zum Zitat Mizera L, Borst O. COVID-19 and the incidence of acute myocardial injury. Hamostaseologie. 2021;41:356–64. PubMedCrossRef Mizera L, Borst O. COVID-19 and the incidence of acute myocardial injury. Hamostaseologie. 2021;41:356–64. PubMedCrossRef
10.
Zurück zum Zitat Hausenloy DJ, Chilian W, Crea F, Davidson SM, Ferdinandy P, Garcia-Dorado D, van Royen N, Schulz R, Heusch G. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. Cardiovasc Res. 2019;115:1143–55. PubMedCrossRef Hausenloy DJ, Chilian W, Crea F, Davidson SM, Ferdinandy P, Garcia-Dorado D, van Royen N, Schulz R, Heusch G. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. Cardiovasc Res. 2019;115:1143–55. PubMedCrossRef
11.
Zurück zum Zitat Rakhit RD, Seiler C, Wustmann K, Zbinden S, Windecker S, Meier B, Eberli FR. Tumour necrosis factor-alpha and interleukin-6 release during primary percutaneous coronary intervention for acute myocardial infarction is related to coronary collateral flow. Coron Artery Dis. 2005;16:147–52. PubMedCrossRef Rakhit RD, Seiler C, Wustmann K, Zbinden S, Windecker S, Meier B, Eberli FR. Tumour necrosis factor-alpha and interleukin-6 release during primary percutaneous coronary intervention for acute myocardial infarction is related to coronary collateral flow. Coron Artery Dis. 2005;16:147–52. PubMedCrossRef
12.
Zurück zum Zitat Zimarino M, D’Andreamatteo M, Waksman R, Epstein SE, De Caterina R. The dynamics of the coronary collateral circulation. Nat Rev Cardiol. 2014;11:191–7. PubMedCrossRef Zimarino M, D’Andreamatteo M, Waksman R, Epstein SE, De Caterina R. The dynamics of the coronary collateral circulation. Nat Rev Cardiol. 2014;11:191–7. PubMedCrossRef
13.
Zurück zum Zitat Liu X, Liu Z, Chen J, Zhu L, Zhang H, Quan X, Yuan Y, Miao H, Huang B, Dong H, Zhang Z. Pigment epithelium-derived factor increases native collateral blood flow to improve cardiac function and induce ventricular remodeling after acute myocardial infarction. J Am Heart Assoc. 2019;8: e013323. PubMedPubMedCentralCrossRef Liu X, Liu Z, Chen J, Zhu L, Zhang H, Quan X, Yuan Y, Miao H, Huang B, Dong H, Zhang Z. Pigment epithelium-derived factor increases native collateral blood flow to improve cardiac function and induce ventricular remodeling after acute myocardial infarction. J Am Heart Assoc. 2019;8: e013323. PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Werner GS, Ferrari M, Betge S, Gastmann O, Richartz BM, Figulla HR. Collateral function in chronic total coronary occlusions is related to regional myocardial function and duration of occlusion. Circulation. 2001;104:2784–90. PubMedCrossRef Werner GS, Ferrari M, Betge S, Gastmann O, Richartz BM, Figulla HR. Collateral function in chronic total coronary occlusions is related to regional myocardial function and duration of occlusion. Circulation. 2001;104:2784–90. PubMedCrossRef
15.
Zurück zum Zitat Seiler C, Stoller M, Pitt B, Meier P. The human coronary collateral circulation: development and clinical importance. Eur Heart J. 2013;34:2674–82. PubMedCrossRef Seiler C, Stoller M, Pitt B, Meier P. The human coronary collateral circulation: development and clinical importance. Eur Heart J. 2013;34:2674–82. PubMedCrossRef
17.
Zurück zum Zitat van der Hoeven NW, Teunissen PF, Werner GS, Delewi R, Schirmer SH, Traupe T, van der Laan AM, Tijssen JG, Piek JJ, Seiler C, van Royen N. Clinical parameters associated with collateral development in patients with chronic total coronary occlusion. Heart. 2013;99:1100–5. PubMedCrossRef van der Hoeven NW, Teunissen PF, Werner GS, Delewi R, Schirmer SH, Traupe T, van der Laan AM, Tijssen JG, Piek JJ, Seiler C, van Royen N. Clinical parameters associated with collateral development in patients with chronic total coronary occlusion. Heart. 2013;99:1100–5. PubMedCrossRef
18.
Zurück zum Zitat Steg PG, Kerner A, Mancini GB, Reynolds HR, Carvalho AC, Fridrich V, White HD, Forman SA, Lamas GA, Hochman JS, Buller CE. Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. Circulation. 2010;121:2724–30. PubMedPubMedCentralCrossRef Steg PG, Kerner A, Mancini GB, Reynolds HR, Carvalho AC, Fridrich V, White HD, Forman SA, Lamas GA, Hochman JS, Buller CE. Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. Circulation. 2010;121:2724–30. PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Kim EK, Choi JH, Song YB, Hahn JY, Chang SA, Park SJ, Lee SC, Choi SH, Choe YH, Park SW, Gwon HC. A protective role of early collateral blood flow in patients with ST-segment elevation myocardial infarction. Am Heart J. 2016;171:56–63. PubMedCrossRef Kim EK, Choi JH, Song YB, Hahn JY, Chang SA, Park SJ, Lee SC, Choi SH, Choe YH, Park SW, Gwon HC. A protective role of early collateral blood flow in patients with ST-segment elevation myocardial infarction. Am Heart J. 2016;171:56–63. PubMedCrossRef
20.
Zurück zum Zitat Das S, Goldstone AB, Wang H, Farry J, D’Amato G, Paulsen MJ, Eskandari A, Hironaka CE, Phansalkar R, Sharma B, Rhee S, Shamskhou EA, Agalliu D, de Jesus PV, Woo YJ, Red-Horse K. A unique collateral artery development program promotes neonatal heart regeneration. Cell. 2019;176:1128-1142.e1118. PubMedPubMedCentralCrossRef Das S, Goldstone AB, Wang H, Farry J, D’Amato G, Paulsen MJ, Eskandari A, Hironaka CE, Phansalkar R, Sharma B, Rhee S, Shamskhou EA, Agalliu D, de Jesus PV, Woo YJ, Red-Horse K. A unique collateral artery development program promotes neonatal heart regeneration. Cell. 2019;176:1128-1142.e1118. PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Park HJ, Chang K, Park CS, Jang SW, Ihm SH, Kim PJ, Baek SH, Seung KB, Choi KB. Coronary collaterals: the role of MCP-1 during the early phase of acute myocardial infarction. Int J Cardiol. 2008;130:409–13. PubMedCrossRef Park HJ, Chang K, Park CS, Jang SW, Ihm SH, Kim PJ, Baek SH, Seung KB, Choi KB. Coronary collaterals: the role of MCP-1 during the early phase of acute myocardial infarction. Int J Cardiol. 2008;130:409–13. PubMedCrossRef
22.
Zurück zum Zitat Meier P, Gloekler S, de Marchi SF, Indermuehle A, Rutz T, Traupe T, Steck H, Vogel R, Seiler C. Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a controlled randomized trial. Circulation. 2009;120:1355–63. PubMedCrossRef Meier P, Gloekler S, de Marchi SF, Indermuehle A, Rutz T, Traupe T, Steck H, Vogel R, Seiler C. Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a controlled randomized trial. Circulation. 2009;120:1355–63. PubMedCrossRef
23.
Zurück zum Zitat Wang W, Yang ZJ, Ma DC, Wang LS, Xu SL, Zhang YR, Cao KJ, Zhang FM, Ma WZ. Induction of collateral artery growth and improvement of post-infarct heart function by hepatocyte growth factor gene transfer. Acta Pharmacol Sin. 2006;27:555–60. PubMedCrossRef Wang W, Yang ZJ, Ma DC, Wang LS, Xu SL, Zhang YR, Cao KJ, Zhang FM, Ma WZ. Induction of collateral artery growth and improvement of post-infarct heart function by hepatocyte growth factor gene transfer. Acta Pharmacol Sin. 2006;27:555–60. PubMedCrossRef
28.
Zurück zum Zitat Bradshaw PC, Seeds WA, Miller AC, Mahajan VR, Curtis WM. COVID-19: proposing a ketone-based metabolic therapy as a treatment to blunt the cytokine storm. Oxid Med Cell Longev. 2020;2020:6401341. PubMedPubMedCentralCrossRef Bradshaw PC, Seeds WA, Miller AC, Mahajan VR, Curtis WM. COVID-19: proposing a ketone-based metabolic therapy as a treatment to blunt the cytokine storm. Oxid Med Cell Longev. 2020;2020:6401341. PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Hartman MHT, Groot HE, Leach IM, Karper JC, van der Harst P. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc Med. 2018;28:369–79. PubMedCrossRef Hartman MHT, Groot HE, Leach IM, Karper JC, van der Harst P. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc Med. 2018;28:369–79. PubMedCrossRef
30.
Zurück zum Zitat Shahrivari M, Wise E, Resende M, Shuster JJ, Zhang J, Bolli R, Cooke JP, Hare JM, Henry TD, Khan A, Taylor DA, Traverse JH, Yang PC, Pepine CJ, Cogle CR. Peripheral blood cytokine levels after acute myocardial infarction: IL-1β- and IL-6-related impairment of bone marrow function. Circ Res. 2017;120:1947–57. PubMedPubMedCentralCrossRef Shahrivari M, Wise E, Resende M, Shuster JJ, Zhang J, Bolli R, Cooke JP, Hare JM, Henry TD, Khan A, Taylor DA, Traverse JH, Yang PC, Pepine CJ, Cogle CR. Peripheral blood cytokine levels after acute myocardial infarction: IL-1β- and IL-6-related impairment of bone marrow function. Circ Res. 2017;120:1947–57. PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Miyamoto T, Touma M, Sasayama S. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol. 2001;38:1546–53. PubMedCrossRef Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, Miyamoto T, Touma M, Sasayama S. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol. 2001;38:1546–53. PubMedCrossRef
32.
Zurück zum Zitat Li Z, Hu S, Huang K, Su T, Cores J, Cheng K. Targeted anti-IL-1β platelet microparticles for cardiac detoxing and repair. Sci Adv 2020;6:eaay0589. Li Z, Hu S, Huang K, Su T, Cores J, Cheng K. Targeted anti-IL-1β platelet microparticles for cardiac detoxing and repair. Sci Adv 2020;6:eaay0589.
33.
Zurück zum Zitat Guillén I, Blanes M, Gómez-Lechón MJ, Castell JV. Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am J Physiol. 1995;269:R229-235. PubMed Guillén I, Blanes M, Gómez-Lechón MJ, Castell JV. Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am J Physiol. 1995;269:R229-235. PubMed
34.
Zurück zum Zitat Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, Mezzaroma E, Dobrina A. Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS ONE. 2011;6: e27923. PubMedPubMedCentralCrossRef Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, Mezzaroma E, Dobrina A. Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS ONE. 2011;6: e27923. PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75–82. PubMedCrossRef Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75–82. PubMedCrossRef
37.
Zurück zum Zitat Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–88. PubMedCrossRef Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–88. PubMedCrossRef
38.
Zurück zum Zitat Xu H, Yang YJ, Qian HY, Tang YD, Wang H, Zhang Q. Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts. Circ J. 2011;75:1476–85. PubMedCrossRef Xu H, Yang YJ, Qian HY, Tang YD, Wang H, Zhang Q. Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts. Circ J. 2011;75:1476–85. PubMedCrossRef
39.
Zurück zum Zitat Xin LH, Liu R, Yang XW. Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway. Eur Rev Med Pharmacol Sci. 2020;24:409–17. PubMed Xin LH, Liu R, Yang XW. Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway. Eur Rev Med Pharmacol Sci. 2020;24:409–17. PubMed
40.
Zurück zum Zitat Zhang S, Liu X, Goldstein S, Li Y, Ge J, He B, Fei X, Wang Z, Ruiz G. Role of the JAK/STAT signaling pathway in the pathogenesis of acute myocardial infarction in rats and its effect on NF-κB expression. Mol Med Rep. 2013;7:93–8. PubMedCrossRef Zhang S, Liu X, Goldstein S, Li Y, Ge J, He B, Fei X, Wang Z, Ruiz G. Role of the JAK/STAT signaling pathway in the pathogenesis of acute myocardial infarction in rats and its effect on NF-κB expression. Mol Med Rep. 2013;7:93–8. PubMedCrossRef
41.
Zurück zum Zitat Krylatov AV, Maslov LN, Voronkov NS, Boshchenko AA, Popov SV, Gomez L, Wang H, Jaggi AS, Downey JM. Reactive oxygen species as intracellular signaling molecules in the cardiovascular system. Curr Cardiol Rev. 2018;14:290–300. PubMedPubMedCentralCrossRef Krylatov AV, Maslov LN, Voronkov NS, Boshchenko AA, Popov SV, Gomez L, Wang H, Jaggi AS, Downey JM. Reactive oxygen species as intracellular signaling molecules in the cardiovascular system. Curr Cardiol Rev. 2018;14:290–300. PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Kan X, Wu Y, Ma Y, Zhang C, Li P, Wu L, Zhang S, Li Y, Du J. Deficiency of IL-12p35 improves cardiac repair after myocardial infarction by promoting angiogenesis. Cardiovasc Res. 2016;109:249–59. PubMedCrossRef Kan X, Wu Y, Ma Y, Zhang C, Li P, Wu L, Zhang S, Li Y, Du J. Deficiency of IL-12p35 improves cardiac repair after myocardial infarction by promoting angiogenesis. Cardiovasc Res. 2016;109:249–59. PubMedCrossRef
43.
Zurück zum Zitat Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996;382:171–4. PubMedCrossRef Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature. 1996;382:171–4. PubMedCrossRef
44.
Zurück zum Zitat Correia LC, Andrade BB, Borges VM, Clarêncio J, Bittencourt AP, Freitas R, Souza AC, Almeida MC, Leal J, Esteves JP, Barral-Netto M. Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes. Clin Chim Acta. 2010;411:540–5. PubMedCrossRef Correia LC, Andrade BB, Borges VM, Clarêncio J, Bittencourt AP, Freitas R, Souza AC, Almeida MC, Leal J, Esteves JP, Barral-Netto M. Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes. Clin Chim Acta. 2010;411:540–5. PubMedCrossRef
45.
Zurück zum Zitat Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton HA, Werman A, Harken AH, Dinarello CA, Banerjee A. Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res. 1999;84:867–75. PubMedCrossRef Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton HA, Werman A, Harken AH, Dinarello CA, Banerjee A. Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res. 1999;84:867–75. PubMedCrossRef
46.
Zurück zum Zitat Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen WH, Shou Z, Liu P. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation. 1999;99:1492–8. PubMedCrossRef Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen WH, Shou Z, Liu P. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation. 1999;99:1492–8. PubMedCrossRef
47.
Zurück zum Zitat Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149–53. PubMedCrossRef Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149–53. PubMedCrossRef
48.
Zurück zum Zitat Neri M, Fineschi V, Di Paolo M, Pomara C, Riezzo I, Turillazzi E, Cerretani D. Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. Curr Vasc Pharmacol. 2015;13:26–36. PubMedCrossRef Neri M, Fineschi V, Di Paolo M, Pomara C, Riezzo I, Turillazzi E, Cerretani D. Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. Curr Vasc Pharmacol. 2015;13:26–36. PubMedCrossRef
49.
Zurück zum Zitat Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY, Lai CC, Liu SH, Liau CS. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal. 2006;18:391–9. PubMedCrossRef Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY, Lai CC, Liu SH, Liau CS. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cell Signal. 2006;18:391–9. PubMedCrossRef
51.
Zurück zum Zitat Onai Y, Suzuki J, Maejima Y, Haraguchi G, Muto S, Itai A, Isobe M. Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292:H530-538. PubMedCrossRef Onai Y, Suzuki J, Maejima Y, Haraguchi G, Muto S, Itai A, Isobe M. Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292:H530-538. PubMedCrossRef
52.
Zurück zum Zitat Natoli G, Costanzo A, Moretti F, Fulco M, Balsano C, Levrero M. J Biol Chem. 1997;272:26079–82. PubMedCrossRef Natoli G, Costanzo A, Moretti F, Fulco M, Balsano C, Levrero M. J Biol Chem. 1997;272:26079–82. PubMedCrossRef
53.
Zurück zum Zitat Morgan MJ, Liu ZG. Reactive oxygen species in TNFalpha-induced signaling and cell death. Mol Cells. 2010;30:1–12. PubMedCrossRef Morgan MJ, Liu ZG. Reactive oxygen species in TNFalpha-induced signaling and cell death. Mol Cells. 2010;30:1–12. PubMedCrossRef
54.
Zurück zum Zitat Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2009;81:457–64. PubMedCrossRef Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2009;81:457–64. PubMedCrossRef
55.
Zurück zum Zitat Sun Y, Wang S, Zhao L, Zhang B, Chen H. IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell. Onco Targets Ther. 2019;12:4907–25. PubMedPubMedCentralCrossRef Sun Y, Wang S, Zhao L, Zhang B, Chen H. IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell. Onco Targets Ther. 2019;12:4907–25. PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–65. PubMedPubMedCentralCrossRef Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–65. PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine. 2013;62:175–82. PubMedCrossRef Song X, Qian Y. The activation and regulation of IL-17 receptor mediated signaling. Cytokine. 2013;62:175–82. PubMedCrossRef
58.
Zurück zum Zitat Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, Woolard J. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. Int J Mol Sci. 2018;19:1264. PubMedCentralCrossRef Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, Woolard J. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. Int J Mol Sci. 2018;19:1264. PubMedCentralCrossRef
59.
Zurück zum Zitat Liu D, Song J, Ji X, Liu Z, Cong M, Hu B. Association of genetic Polymorphisms on VEGFA and VEGFR2 with risk of coronary heart disease. Medicine (Baltimore). 2016;95: e3413. PubMedPubMedCentralCrossRef Liu D, Song J, Ji X, Liu Z, Cong M, Hu B. Association of genetic Polymorphisms on VEGFA and VEGFR2 with risk of coronary heart disease. Medicine (Baltimore). 2016;95: e3413. PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336–43. PubMedCrossRef Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336–43. PubMedCrossRef
61.
Zurück zum Zitat McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem. 2005;280:20995–1003. PubMedCrossRef McMullen ME, Bryant PW, Glembotski CC, Vincent PA, Pumiglia KM. Activation of p38 has opposing effects on the proliferation and migration of endothelial cells. J Biol Chem. 2005;280:20995–1003. PubMedCrossRef
62.
Zurück zum Zitat Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD. VEGF-induced vascular permeability is mediated by FAK. Dev Cell. 2012;22:146–57. PubMedPubMedCentralCrossRef Chen XL, Nam JO, Jean C, Lawson C, Walsh CT, Goka E, Lim ST, Tomar A, Tancioni I, Uryu S, Guan JL, Acevedo LM, Weis SM, Cheresh DA, Schlaepfer DD. VEGF-induced vascular permeability is mediated by FAK. Dev Cell. 2012;22:146–57. PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. Embo j. 2001;20:2768–78. PubMedPubMedCentralCrossRef Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. Embo j. 2001;20:2768–78. PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999;18:2221–30. PubMedCrossRef Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999;18:2221–30. PubMedCrossRef
65.
Zurück zum Zitat Yang B, Yan P, Gong H, Zuo L, Shi Y, Guo J, Guo R, Xie J, Li B. TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent manner. Am J Transl Res. 2016;8:3848–60. PubMedPubMedCentral Yang B, Yan P, Gong H, Zuo L, Shi Y, Guo J, Guo R, Xie J, Li B. TWEAK protects cardiomyocyte against apoptosis in a PI3K/AKT pathway dependent manner. Am J Transl Res. 2016;8:3848–60. PubMedPubMedCentral
66.
Zurück zum Zitat Zou J, Fei Q, Xiao H, Wang H, Liu K, Liu M, Zhang H, Xiao X, Wang K, Wang N. VEGF-A promotes angiogenesis after acute myocardial infarction through increasing ROS production and enhancing ER stress-mediated autophagy. J Cell Physiol. 2019;234:17690–703. PubMedCrossRef Zou J, Fei Q, Xiao H, Wang H, Liu K, Liu M, Zhang H, Xiao X, Wang K, Wang N. VEGF-A promotes angiogenesis after acute myocardial infarction through increasing ROS production and enhancing ER stress-mediated autophagy. J Cell Physiol. 2019;234:17690–703. PubMedCrossRef
67.
Zurück zum Zitat Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, Mysiak A, Orda A, Poreba R, Mazurek W. Chemokines and left ventricular function in patients with acute myocardial infarction. Eur J Intern Med. 2007;18:288–94. PubMedCrossRef Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, Mysiak A, Orda A, Poreba R, Mazurek W. Chemokines and left ventricular function in patients with acute myocardial infarction. Eur J Intern Med. 2007;18:288–94. PubMedCrossRef
68.
Zurück zum Zitat Sahinarslan A, Kocaman SA, Topal S, Ercin U, Bukan N, Yalcin R, Timurkaynak T. Relation between serum monocyte chemoattractant protein-1 and coronary collateral development. Coron Artery Dis. 2010;21:455–9. PubMedCrossRef Sahinarslan A, Kocaman SA, Topal S, Ercin U, Bukan N, Yalcin R, Timurkaynak T. Relation between serum monocyte chemoattractant protein-1 and coronary collateral development. Coron Artery Dis. 2010;21:455–9. PubMedCrossRef
69.
Zurück zum Zitat Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE, Ikeda U. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res. 2006;99:891–9. PubMedCrossRef Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE, Ikeda U. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res. 2006;99:891–9. PubMedCrossRef
70.
Zurück zum Zitat Frangogiannis NG, Dewald O, Xia Y, Ren G, Haudek S, Leucker T, Kraemer D, Taffet G, Rollins BJ, Entman ML. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation. 2007;115:584–92. PubMedCrossRef Frangogiannis NG, Dewald O, Xia Y, Ren G, Haudek S, Leucker T, Kraemer D, Taffet G, Rollins BJ, Entman ML. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation. 2007;115:584–92. PubMedCrossRef
71.
Zurück zum Zitat Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG. CCL2/Monocyte Chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res. 2005;96:881–9. PubMedCrossRef Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG. CCL2/Monocyte Chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res. 2005;96:881–9. PubMedCrossRef
72.
Zurück zum Zitat Weir RA, Murphy CA, Petrie CJ, Martin TN, Clements S, Steedman T, Wagner GS, McMurray JJ, Dargie HJ. Monocyte chemoattractant protein-1: a dichotomous role in cardiac remodeling following acute myocardial infarction in man? Cytokine. 2010;50:158–62. PubMedCrossRef Weir RA, Murphy CA, Petrie CJ, Martin TN, Clements S, Steedman T, Wagner GS, McMurray JJ, Dargie HJ. Monocyte chemoattractant protein-1: a dichotomous role in cardiac remodeling following acute myocardial infarction in man? Cytokine. 2010;50:158–62. PubMedCrossRef
73.
Zurück zum Zitat França CN, Izar MCO, Hortêncio MNS, do Amaral JB, Ferreira CES, Tuleta ID, Fonseca FAH. Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease. Clin Sci (Lond) 2017;131:1215–1224. França CN, Izar MCO, Hortêncio MNS, do Amaral JB, Ferreira CES, Tuleta ID, Fonseca FAH. Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease. Clin Sci (Lond) 2017;131:1215–1224.
74.
Zurück zum Zitat Khalil H, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, Vagnozzi RJ, Liu R, Huynh T, Lee SJ, Karch J, Molkentin JD. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest. 2017;127:3770–83. PubMedPubMedCentralCrossRef Khalil H, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, Vagnozzi RJ, Liu R, Huynh T, Lee SJ, Karch J, Molkentin JD. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest. 2017;127:3770–83. PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325–38. PubMedCrossRef Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325–38. PubMedCrossRef
76.
Zurück zum Zitat Ma J, Li ZY, Liang XP, Guo CX, Lu PP, Ma LH. Xinfuli Granule improves post-myocardial infarction ventricular remodeling and myocardial fibrosis in rats by regulating TGF-β/Smads signaling pathway. J Geriatr Cardiol. 2017;14:301–7. PubMedPubMedCentral Ma J, Li ZY, Liang XP, Guo CX, Lu PP, Ma LH. Xinfuli Granule improves post-myocardial infarction ventricular remodeling and myocardial fibrosis in rats by regulating TGF-β/Smads signaling pathway. J Geriatr Cardiol. 2017;14:301–7. PubMedPubMedCentral
77.
Zurück zum Zitat Gao L, Wang LY, Liu ZQ, Jiang D, Wu SY, Guo YQ, Tao HM, Sun M, You LN, Qin S, Cheng XC, Xie JS, Chang GL, Zhang DY. TNAP inhibition attenuates cardiac fibrosis induced by myocardial infarction through deactivating TGF-β1/Smads and activating P53 signaling pathways. Cell Death Dis. 2020;11:44. PubMedPubMedCentralCrossRef Gao L, Wang LY, Liu ZQ, Jiang D, Wu SY, Guo YQ, Tao HM, Sun M, You LN, Qin S, Cheng XC, Xie JS, Chang GL, Zhang DY. TNAP inhibition attenuates cardiac fibrosis induced by myocardial infarction through deactivating TGF-β1/Smads and activating P53 signaling pathways. Cell Death Dis. 2020;11:44. PubMedPubMedCentralCrossRef
78.
Zurück zum Zitat Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184–95. PubMedCrossRef Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184–95. PubMedCrossRef
79.
Zurück zum Zitat Chillo O, Kleinert EC, Lautz T, Lasch M, Pagel JI, Heun Y, Troidl K, Fischer S, Caballero-Martinez A, Mauer A, Kurz ARM, Assmann G, Rehberg M, Kanse SM, Nieswandt B, Walzog B, Reichel CA, Mannell H, Preissner KT, Deindl E. Perivascular mast cells govern shear stress-induced arteriogenesis by orchestrating leukocyte function. Cell Rep. 2016;16:2197–207. PubMedCrossRef Chillo O, Kleinert EC, Lautz T, Lasch M, Pagel JI, Heun Y, Troidl K, Fischer S, Caballero-Martinez A, Mauer A, Kurz ARM, Assmann G, Rehberg M, Kanse SM, Nieswandt B, Walzog B, Reichel CA, Mannell H, Preissner KT, Deindl E. Perivascular mast cells govern shear stress-induced arteriogenesis by orchestrating leukocyte function. Cell Rep. 2016;16:2197–207. PubMedCrossRef
80.
Zurück zum Zitat Lasch M, Kleinert EC, Meister S, Kumaraswami K, Buchheim JI, Grantzow T, Lautz T, Salpisti S, Fischer S, Troidl K, Fleming I, Randi AM, Sperandio M, Preissner KT, Deindl E. Extracellular RNA released due to shear stress controls natural bypass growth by mediating mechanotransduction in mice. Blood. 2019;134:1469–79. PubMedCrossRef Lasch M, Kleinert EC, Meister S, Kumaraswami K, Buchheim JI, Grantzow T, Lautz T, Salpisti S, Fischer S, Troidl K, Fleming I, Randi AM, Sperandio M, Preissner KT, Deindl E. Extracellular RNA released due to shear stress controls natural bypass growth by mediating mechanotransduction in mice. Blood. 2019;134:1469–79. PubMedCrossRef
81.
Zurück zum Zitat Kluever AK, Braumandl A, Fischer S, Preissner KT, Deindl E. The extraordinary role of extracellular rna in arteriogenesis, the growth of collateral arteries. Int J Mol Sci. 2019;20:6177. PubMedCentralCrossRef Kluever AK, Braumandl A, Fischer S, Preissner KT, Deindl E. The extraordinary role of extracellular rna in arteriogenesis, the growth of collateral arteries. Int J Mol Sci. 2019;20:6177. PubMedCentralCrossRef
83.
Zurück zum Zitat Deem TL, Abdala-Valencia H, Cook-Mills JM. VCAM-1 activation of endothelial cell protein tyrosine phosphatase 1B. J Immunol. 2007;178:3865–73. PubMedCrossRef Deem TL, Abdala-Valencia H, Cook-Mills JM. VCAM-1 activation of endothelial cell protein tyrosine phosphatase 1B. J Immunol. 2007;178:3865–73. PubMedCrossRef
84.
85.
Zurück zum Zitat Li W, Liu C, Burns N, Hayashi J, Yoshida A, Sajja A, González-Hernández S, Gao JL, Murphy PM, Kubota Y, Zou YR, Nagasawa T, Mukouyama YS. Alterations in the spatiotemporal expression of the chemokine receptor CXCR4 in endothelial cells cause failure of hierarchical vascular branching. Dev Biol. 2021;477:70–84. PubMedPubMedCentralCrossRef Li W, Liu C, Burns N, Hayashi J, Yoshida A, Sajja A, González-Hernández S, Gao JL, Murphy PM, Kubota Y, Zou YR, Nagasawa T, Mukouyama YS. Alterations in the spatiotemporal expression of the chemokine receptor CXCR4 in endothelial cells cause failure of hierarchical vascular branching. Dev Biol. 2021;477:70–84. PubMedPubMedCentralCrossRef
86.
Zurück zum Zitat Gu Q, Yang XP, Bonde P, DiPaula A, Fox-Talbot K, Becker LC. Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. J Cardiovasc Pharmacol. 2006;48:320–8. PubMedCrossRef Gu Q, Yang XP, Bonde P, DiPaula A, Fox-Talbot K, Becker LC. Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. J Cardiovasc Pharmacol. 2006;48:320–8. PubMedCrossRef
87.
88.
Zurück zum Zitat Chu H, Wang Y. Therapeutic angiogenesis: controlled delivery of angiogenic factors. Ther Deliv. 2012;3:693–714. PubMedCrossRef Chu H, Wang Y. Therapeutic angiogenesis: controlled delivery of angiogenic factors. Ther Deliv. 2012;3:693–714. PubMedCrossRef
89.
Zurück zum Zitat Xu Y, Tang T, Ding Y, Yao R, Xie J, Liao M, Xiao H, Chen Y, Yu X, Fu M, Liao Y, Zhao G, Cheng X. Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. Am J Med Sci. 2010;340:121–7. PubMedCrossRef Xu Y, Tang T, Ding Y, Yao R, Xie J, Liao M, Xiao H, Chen Y, Yu X, Fu M, Liao Y, Zhao G, Cheng X. Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. Am J Med Sci. 2010;340:121–7. PubMedCrossRef
90.
Zurück zum Zitat Bao JW, Sun B, Ma PP, Gai YS, Sun WZ, Yu HQ, Li J. Rosuvastatin inhibits inflammatory response and resists fibrosis after myocardial infarction. Eur Rev Med Pharmacol Sci. 2018;22:238–45. PubMed Bao JW, Sun B, Ma PP, Gai YS, Sun WZ, Yu HQ, Li J. Rosuvastatin inhibits inflammatory response and resists fibrosis after myocardial infarction. Eur Rev Med Pharmacol Sci. 2018;22:238–45. PubMed
91.
Zurück zum Zitat Zaitone SA, Abo-Gresha NM. Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF. Eur J Pharmacol. 2012;691:134–42. PubMedCrossRef Zaitone SA, Abo-Gresha NM. Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF. Eur J Pharmacol. 2012;691:134–42. PubMedCrossRef
92.
Zurück zum Zitat Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002;22:1194–9. PubMedCrossRef Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002;22:1194–9. PubMedCrossRef
93.
Zurück zum Zitat Li TS, Takahashi M, Suzuki R, Kobayashi T, Ito H, Mikamo A, Hamano K. Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis. Ann Thorac Surg. 2006;81:2217–25. PubMedCrossRef Li TS, Takahashi M, Suzuki R, Kobayashi T, Ito H, Mikamo A, Hamano K. Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis. Ann Thorac Surg. 2006;81:2217–25. PubMedCrossRef
94.
Zurück zum Zitat Lu W, Xie Z, Tang Y, Bai L, Yao Y, Fu C, Ma G. Photoluminescent Mesoporous silicon nanoparticles with siCCR2 improve the effects of mesenchymal stromal cell transplantation after acute myocardial infarction. Theranostics. 2015;5:1068–82. PubMedPubMedCentralCrossRef Lu W, Xie Z, Tang Y, Bai L, Yao Y, Fu C, Ma G. Photoluminescent Mesoporous silicon nanoparticles with siCCR2 improve the effects of mesenchymal stromal cell transplantation after acute myocardial infarction. Theranostics. 2015;5:1068–82. PubMedPubMedCentralCrossRef
95.
Zurück zum Zitat Wang J, Seo MJ, Deci MB, Weil BR, Canty JM, Nguyen J. Effect of CCR2 inhibitor-loaded lipid micelles on inflammatory cell migration and cardiac function after myocardial infarction. Int J Nanomedicine. 2018;13:6441–51. PubMedPubMedCentralCrossRef Wang J, Seo MJ, Deci MB, Weil BR, Canty JM, Nguyen J. Effect of CCR2 inhibitor-loaded lipid micelles on inflammatory cell migration and cardiac function after myocardial infarction. Int J Nanomedicine. 2018;13:6441–51. PubMedPubMedCentralCrossRef
96.
Zurück zum Zitat Liehn EA, Piccinini AM, Koenen RR, Soehnlein O, Adage T, Fatu R, Curaj A, Popescu A, Zernecke A, Kungl AJ, Weber C. A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol. 2010;56:1847–57. PubMedCrossRef Liehn EA, Piccinini AM, Koenen RR, Soehnlein O, Adage T, Fatu R, Curaj A, Popescu A, Zernecke A, Kungl AJ, Weber C. A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol. 2010;56:1847–57. PubMedCrossRef
97.
Zurück zum Zitat Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111:1394–400. PubMedPubMedCentralCrossRef Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111:1394–400. PubMedPubMedCentralCrossRef
99.
Zurück zum Zitat Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, Sota J, Dinarello CA. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20: 102763. PubMedCrossRef Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, Sota J, Dinarello CA. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20: 102763. PubMedCrossRef
100.
Zurück zum Zitat Zhang J, Huang L, Shi X, Yang L, Hua F, Ma J, Zhu W, Liu X, Xuan R, Shen Y, Liu J, Lai X, Yu P. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway. Aging (Albany NY). 2020;12:24270–87. CrossRef Zhang J, Huang L, Shi X, Yang L, Hua F, Ma J, Zhu W, Liu X, Xuan R, Shen Y, Liu J, Lai X, Yu P. Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway. Aging (Albany NY). 2020;12:24270–87. CrossRef
101.
Zurück zum Zitat Emran T, Chowdhury NI, Sarker M, Bepari AK, Hossain M, Rahman GMS, Reza HM. L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction. Biomed Pharmacother. 2021;143: 112139. PubMedCrossRef Emran T, Chowdhury NI, Sarker M, Bepari AK, Hossain M, Rahman GMS, Reza HM. L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction. Biomed Pharmacother. 2021;143: 112139. PubMedCrossRef
102.
Zurück zum Zitat Feng H, Mou SQ, Li WJ, Zhang N, Zhou ZY, Ding W, Bian ZY, Liao HH. Resveratrol inhibits ischemia-induced myocardial senescence signals and NLRP3 inflammasome activation. Oxid Med Cell Longev. 2020;2020:2647807. PubMedPubMedCentralCrossRef Feng H, Mou SQ, Li WJ, Zhang N, Zhou ZY, Ding W, Bian ZY, Liao HH. Resveratrol inhibits ischemia-induced myocardial senescence signals and NLRP3 inflammasome activation. Oxid Med Cell Longev. 2020;2020:2647807. PubMedPubMedCentralCrossRef
103.
Zurück zum Zitat Xu GR, Zhang C, Yang HX, Sun JH, Zhang Y, Yao TT, Li Y, Ruan L, An R, Li AY. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway. Biomed Pharmacother. 2020;126: 110071. PubMedCrossRef Xu GR, Zhang C, Yang HX, Sun JH, Zhang Y, Yao TT, Li Y, Ruan L, An R, Li AY. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway. Biomed Pharmacother. 2020;126: 110071. PubMedCrossRef
104.
Zurück zum Zitat Bai Y, Li Z, Liu W, Gao D, Liu M, Zhang P. Biochanin A attenuates myocardial ischemia/reperfusion injury through the TLR4/NF-κB/NLRP3 signaling pathway. Acta Cir Bras. 2019;34: e201901104. PubMedPubMedCentralCrossRef Bai Y, Li Z, Liu W, Gao D, Liu M, Zhang P. Biochanin A attenuates myocardial ischemia/reperfusion injury through the TLR4/NF-κB/NLRP3 signaling pathway. Acta Cir Bras. 2019;34: e201901104. PubMedPubMedCentralCrossRef
105.
Zurück zum Zitat Oduk Y, Zhu W, Kannappan R, Zhao M, Borovjagin AV, Oparil S, Zhang JJ. VEGF nanoparticles repair the heart after myocardial infarction. Am J Physiol Heart Circ Physiol. 2018;314:H278-h284. PubMedCrossRef Oduk Y, Zhu W, Kannappan R, Zhao M, Borovjagin AV, Oparil S, Zhang JJ. VEGF nanoparticles repair the heart after myocardial infarction. Am J Physiol Heart Circ Physiol. 2018;314:H278-h284. PubMedCrossRef
106.
Zurück zum Zitat Awada HK, Johnson NR, Wang Y. Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction. J Control Release. 2015;207:7–17. PubMedPubMedCentralCrossRef Awada HK, Johnson NR, Wang Y. Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction. J Control Release. 2015;207:7–17. PubMedPubMedCentralCrossRef
107.
108.
Zurück zum Zitat Ferraro B, Leoni G, Hinkel R, Ormanns S, Paulin N, Ortega-Gomez A, Viola JR, de Jong R, Bongiovanni D, Bozoglu T, Maas SL, D’Amico M, Kessler T, Zeller T, Hristov M, Reutelingsperger C, Sager HB, Döring Y, Nahrendorf M, Kupatt C, Soehnlein O. Pro-angiogenic macrophage phenotype to promote myocardial repair. J Am Coll Cardiol. 2019;73:2990–3002. PubMedCrossRef Ferraro B, Leoni G, Hinkel R, Ormanns S, Paulin N, Ortega-Gomez A, Viola JR, de Jong R, Bongiovanni D, Bozoglu T, Maas SL, D’Amico M, Kessler T, Zeller T, Hristov M, Reutelingsperger C, Sager HB, Döring Y, Nahrendorf M, Kupatt C, Soehnlein O. Pro-angiogenic macrophage phenotype to promote myocardial repair. J Am Coll Cardiol. 2019;73:2990–3002. PubMedCrossRef
109.
Zurück zum Zitat Feng L, Ren J, Li Y, Yang G, Kang L, Zhang S, Ma C, Li J, Liu J, Yang L, Qi Z. Resveratrol protects against isoproterenol induced myocardial infarction in rats through VEGF-B/AMPK/eNOS/NO signalling pathway. Free Radic Res. 2019;53:82–93. PubMedCrossRef Feng L, Ren J, Li Y, Yang G, Kang L, Zhang S, Ma C, Li J, Liu J, Yang L, Qi Z. Resveratrol protects against isoproterenol induced myocardial infarction in rats through VEGF-B/AMPK/eNOS/NO signalling pathway. Free Radic Res. 2019;53:82–93. PubMedCrossRef
110.
Zurück zum Zitat Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600–6. PubMedCrossRef Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600–6. PubMedCrossRef
112.
Zurück zum Zitat Grundmann S, van Royen N, Pasterkamp G, Gonzalez N, Tijsma EJ, Piek JJ, Hoefer IE. A new intra-arterial delivery platform for pro-arteriogenic compounds to stimulate collateral artery growth via transforming growth factor-beta1 release. J Am Coll Cardiol. 2007;50:351–8. PubMedCrossRef Grundmann S, van Royen N, Pasterkamp G, Gonzalez N, Tijsma EJ, Piek JJ, Hoefer IE. A new intra-arterial delivery platform for pro-arteriogenic compounds to stimulate collateral artery growth via transforming growth factor-beta1 release. J Am Coll Cardiol. 2007;50:351–8. PubMedCrossRef
113.
Zurück zum Zitat Daud E, Ertracht O, Bandel N, Moady G, Shehadeh M, Reuveni T, Atar S. The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats. Cardiovasc Diabetol. 2021;20:132. PubMedPubMedCentralCrossRef Daud E, Ertracht O, Bandel N, Moady G, Shehadeh M, Reuveni T, Atar S. The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats. Cardiovasc Diabetol. 2021;20:132. PubMedPubMedCentralCrossRef
114.
Zurück zum Zitat Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, Guzzardi DG, Svystonyuk DA, Pattar SS, Park DSJ, Turnbull JD, Duff HJ, Tibbles LA, Cunnington RH, Dyck JRB, Fedak PWM. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG outcome results. Can J Cardiol. 2020;36:543–53. PubMedCrossRef Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, Guzzardi DG, Svystonyuk DA, Pattar SS, Park DSJ, Turnbull JD, Duff HJ, Tibbles LA, Cunnington RH, Dyck JRB, Fedak PWM. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG outcome results. Can J Cardiol. 2020;36:543–53. PubMedCrossRef
115.
Zurück zum Zitat Wang N, Liu C, Wang X, He T, Li L, Liang X, Wang L, Song L, Wei Y, Wu Q, Gong C. Hyaluronic acid oligosaccharides improve myocardial function reconstruction and angiogenesis against myocardial infarction by regulation of macrophages. Theranostics. 2019;9:1980–92. PubMedPubMedCentralCrossRef Wang N, Liu C, Wang X, He T, Li L, Liang X, Wang L, Song L, Wei Y, Wu Q, Gong C. Hyaluronic acid oligosaccharides improve myocardial function reconstruction and angiogenesis against myocardial infarction by regulation of macrophages. Theranostics. 2019;9:1980–92. PubMedPubMedCentralCrossRef
116.
Zurück zum Zitat López-Sanromán A, Esplugues JV, Domènech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol. 2021;44:39–48. PubMedCrossRef López-Sanromán A, Esplugues JV, Domènech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol. 2021;44:39–48. PubMedCrossRef
117.
Zurück zum Zitat Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379:645–8. PubMedCrossRef Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379:645–8. PubMedCrossRef
118.
Zurück zum Zitat Jiang Y, Feng YP, Tang LX, Yan YL, Bai JW. The protective role of NR4A3 in acute myocardial infarction by suppressing inflammatory responses via JAK2-STAT3/NF-κB pathway. Biochem Biophys Res Commun. 2019;517:697–702. PubMedCrossRef Jiang Y, Feng YP, Tang LX, Yan YL, Bai JW. The protective role of NR4A3 in acute myocardial infarction by suppressing inflammatory responses via JAK2-STAT3/NF-κB pathway. Biochem Biophys Res Commun. 2019;517:697–702. PubMedCrossRef
119.
Zurück zum Zitat Lai XX, Zhang N, Chen LY, Luo YY, Shou BY, Xie XX, Liu RH. Latifolin protects against myocardial infarction by alleviating myocardial inflammatory via the HIF-1α/NF-κB/IL-6 pathway. Pharm Biol. 2020;58:1156–66. PubMedCrossRef Lai XX, Zhang N, Chen LY, Luo YY, Shou BY, Xie XX, Liu RH. Latifolin protects against myocardial infarction by alleviating myocardial inflammatory via the HIF-1α/NF-κB/IL-6 pathway. Pharm Biol. 2020;58:1156–66. PubMedCrossRef
120.
Zurück zum Zitat Zhang X, Li M, Wang H. Astragaloside IV alleviates the myocardial damage induced by lipopolysaccharide via the toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB)/proliferator-activated receptor α (PPARα) Signaling Pathway. Med Sci Monit. 2019;25:7158–68. PubMedPubMedCentralCrossRef Zhang X, Li M, Wang H. Astragaloside IV alleviates the myocardial damage induced by lipopolysaccharide via the toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB)/proliferator-activated receptor α (PPARα) Signaling Pathway. Med Sci Monit. 2019;25:7158–68. PubMedPubMedCentralCrossRef
121.
Zurück zum Zitat Yu B, Wang W. Cardioprotective effects of morroniside in rats following acute myocardial infarction. Inflammation. 2018;41:432–6. PubMedCrossRef Yu B, Wang W. Cardioprotective effects of morroniside in rats following acute myocardial infarction. Inflammation. 2018;41:432–6. PubMedCrossRef
122.
Zurück zum Zitat Chen X, Li X, Zhang W, He J, Xu B, Lei B, Wang Z, Cates C, Rousselle T, Li J. Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-κB pathway. Metabolism. 2018;83:256–70. PubMedPubMedCentralCrossRef Chen X, Li X, Zhang W, He J, Xu B, Lei B, Wang Z, Cates C, Rousselle T, Li J. Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-κB pathway. Metabolism. 2018;83:256–70. PubMedPubMedCentralCrossRef
123.
Zurück zum Zitat Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-Vigdal A, Karpinski S, Kornyeyev D, Adamkewicz J, Feng X, Zhou Q, Shang C, Kumar P, Phan D, Kasner M, López B, Diez J, Wright KC, Kovacs RL, Chen PS, Quertermous T, Smith V, Yao L, Tschöpe C, Chang CP. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun. 2016;7:13710. PubMedPubMedCentralCrossRef Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-Vigdal A, Karpinski S, Kornyeyev D, Adamkewicz J, Feng X, Zhou Q, Shang C, Kumar P, Phan D, Kasner M, López B, Diez J, Wright KC, Kovacs RL, Chen PS, Quertermous T, Smith V, Yao L, Tschöpe C, Chang CP. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun. 2016;7:13710. PubMedPubMedCentralCrossRef
124.
Zurück zum Zitat Dai Y, Chen Y, Wei G, Zha L, Li X. Ivabradine protects rats against myocardial infarction through reinforcing autophagy via inhibiting PI3K/AKT/mTOR/p70S6K pathway. Bioengineered. 2021;12:1826–37. PubMedPubMedCentralCrossRef Dai Y, Chen Y, Wei G, Zha L, Li X. Ivabradine protects rats against myocardial infarction through reinforcing autophagy via inhibiting PI3K/AKT/mTOR/p70S6K pathway. Bioengineered. 2021;12:1826–37. PubMedPubMedCentralCrossRef
125.
Zurück zum Zitat Yu Y, Hu Z, Li B, Wang Z, Chen S. Ivabradine improved left ventricular function and pressure overload-induced cardiomyocyte apoptosis in a transverse aortic constriction mouse model. Mol Cell Biochem. 2019;450:25–34. PubMedCrossRef Yu Y, Hu Z, Li B, Wang Z, Chen S. Ivabradine improved left ventricular function and pressure overload-induced cardiomyocyte apoptosis in a transverse aortic constriction mouse model. Mol Cell Biochem. 2019;450:25–34. PubMedCrossRef
Metadaten
Titel
Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction
verfasst von
Weixin He
Peixian Chen
Qingquan Chen
Zongtong Cai
Peidong Zhang
Publikationsdatum
25.07.2022
Verlag
Springer International Publishing
Erschienen in
Inflammation Research / Ausgabe 10-11/2022
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-022-01611-0

Weitere Artikel der Ausgabe 10-11/2022

Inflammation Research 10-11/2022 Zur Ausgabe

Update Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.